Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ketamine + rapamycin
- Development stage
- Phase 2
- Lead developer
- Freedom Biosciences
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of ketamine and rapamycin. Ketamine is an NMDA receptor antagonist with rapid antidepressant effects, while rapamycin is an mTORC1 inhibitor. When administered together, rapamycin appears to prolong the antidepressant effects of ketamine. In clinical trials, pretreatment with rapamycin (6 mg) before ketamine infusion (0.5 mg/kg) resulted in higher response and remission rates at two weeks compared to ketamine alone.
02
Targets
Mechanistic target of rapamycin complex 1NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on ketamine + rapamycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ketamine + rapamycin.